• 1
    Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 63848.
  • 2
    Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 13619.
  • 3
    Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 265564.
  • 4
    Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 2332.
  • 5
    Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 6473.
  • 6
    Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ECL cell carcinoids. APMIS 1999; 107: 108592.
  • 7
    Spampatti MP, Massironi S, Rossi RE, et al. Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature. Eur J Gastroenterol Hepatol 2012; 24: 58993.
  • 8
    Sjöblom SM, Sipponen P, Miettinen M, Karonen SL, Jrvinen HJ. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy 1988; 20: 526.
  • 9
    Kokkola A, Sjöblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33: 8892.
  • 10
    Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002; 110: 1329.
  • 11
    Waldum HL, Qvigstad G, Falkmer S. Indications for a neuroendocrine tumor-carcinoma sequence. Virchows Arch 2001; 439: 2157.
  • 12
    Ruszniewski P, Delle Fave G, Cadiot G, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 2006; 84: 15864.
  • 13
    Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004; 39: 6218.
  • 14
    Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 2005; 40: 126974.
  • 15
    Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159: 47582.
  • 16
    Jianu CS, Fossmark R, Syversen U, Hauso O, Fykse V, Waldum HL. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 2011; 46: 45663.
  • 17
    Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95: 20713.
  • 18
    Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102: 140918.
  • 19
    Kern SE, Yardley JH, Lazenby AJ, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol 1990; 3: 5616.
  • 20
    Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 1988; 104: 104653.
  • 21
    Wangberg B, Grimelius L, Granerus G, Conradi N, Jansson S, Ahlman H. The role of gastric resection in the management of multicentric argyrophil gastric carcinoids. Surgery 1990; 108: 8517.
  • 22
    Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 2010; 162: 225.
  • 23
    Takinami Y, Yuki H, Nishida A, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997; 11: 11320.
  • 24
    Boyce M, Warrington S, Nentwich H, Norris V, Hull R, Black J. Effect of repeated doses of YF476, a gastrin antagonist, on pentagastrin-induced changes in volume, H+ content and pH of gastric aspirate in healthy subjects. Br J Clin Pharmacol 2004; 57: 684.
  • 25
    Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 1819.
  • 26
    Martinsen TC, Kawase S, Hakanson R, et al. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 2003; 24: 188796.
  • 27
    Takaishi S, Cui G, Frederick DM, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005; 128: 196583.
  • 28
    Kidd M, Siddique ZL, Drozdov I, et al. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 2010; 162: 5260.
  • 29
    Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185200.
  • 30
    Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985; 20: 56976.
  • 31
    Redrup MJ, Leaf FC, Miyashita A, et al. Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772: 31725.
  • 32
    Tielemans Y, Axelson J, Sundler F, Willems G, Håkanson R. Serum gastrin concentration affects the self replication rate of the enterochromaffin like cells in the rat stomach. Gut 1990; 96: 2748.
  • 33
    Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000; 169: 2937.
  • 34
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35(Suppl. 1): 4255.
  • 35
    Havu N, Mattsson H, Ekman L, Carlsson E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 18995.
  • 36
    Poynter D, Selway SA, Papworth SA, Riches SR. Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut 1986; 27: 133846.
  • 37
    Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118: 3647.
  • 38
    Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res 1998; 58: 42559.
  • 39
    Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115: 6428.
  • 40
    Nilsson O, Wangberg B, Johansson L, et al. Rapid induction of enterochromaffinlike cell tumors by histamine2-receptor blockade. Am J Pathol 1993; 142: 117385.
  • 41
    Waldum HL, Rørvik H, Falkmer S, Kawase S. Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab Anim Sci 1999; 49: 2417.
  • 42
    Fossmark R, Martinsen TC, Bakkelund KE, Kawase S, Waldum HL. ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Res 2004; 64: 368793.
  • 43
    Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83: 4383.
  • 44
    Cadiot G, Vissuzaine C, Potet F, Mignon M. Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 1995; 40: 12758.
  • 45
    Richards ML, Gauger P, Thompson NW, Giordano TJ. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg 2004; 28: 6528.
  • 46
    Black JW, Kalindjian SB. Gastrin agonists and antagonists. Pharmacol Toxicol 2002; 91: 27581.
  • 47
    Boyce M, Warrington S, Johnston A, Harris A. Effect on gastric pH of single doses of YF476, a new gastrin antagonist, compared with ranitidine and placebo. Br J Clin Pharmacol 2000; 50: 383P4P.
  • 48
    Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43: 204.
  • 49
    Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 4438.
  • 50
    Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21: 14954.
  • 51
    Ojeaburu JV, Ito T, Crafa P, Bordi C, Jensen RT. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011; 56: 13954.
  • 52
    Guillem P. Les tumeurs carcinoides de l'estomac. Quelle place pour l'antrectomie? Ann Chir 2005; 130: 3236.
  • 53
    Guillem P, Vlaeminck-Guillem V, Leteurtre E, et al. Tumeurs endocrines fundiques sur gastrite atrophique: interet de l'antrectomie. Gastroenterol Clin Biol 2002; 26: 7825.